Promising Safety and Efficacy of Nuvectis Pharma’s NXP900 Drives Buy Recommendation

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target remains the same with $10.00.

Joseph Pantginis has given his Buy rating due to a combination of factors including the promising safety profile and pharmacodynamic activity of Nuvectis Pharma’s NXP900. The drug, which is being tested in patients with advanced solid tumors, has shown acceptable safety with primarily mild side effects such as Grade 1-2 diarrhea, fatigue, and nausea. Additionally, the drug exhibits linear dose-exposure and robust pharmacodynamic activity at doses of 150 mg and above, which is encouraging for its continued development.
Furthermore, a drug-drug interaction study in healthy volunteers indicated that NXP900 does not induce key CYP450 enzymes, which supports its potential for safe use in combination therapies. The pooled analysis also demonstrated that NXP900 effectively reduces phosphorylated SRC in peripheral blood mononuclear cells at steady state, confirming strong target engagement. These positive clinical findings underpin Pantginis’s confidence in the stock, leading to his Buy recommendation.